Retour

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stocks Changes in company's own shares

BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 5,400 shares of its common stock under the Company’s 2023 Inducement Plan.

GlobeNewswire Inc. • 26/04/2024 à 22:05:00
Tempest Therapeutics, Inc. Common Stock
Address: 2000 SIERRA POINT PARKWAY
Postal Code: 94005
City: BRISBANE
State: CA
Phone Number: 415-798-8589
Website: https://www.tempesttx.com
Status: Active
Company Info

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

List Date2021-06-28
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001544227
Composite figiBBG002NDK339
Share Class figiBBG002NDK348
Market Cap81,981,708 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees17
Share Class Shares Outstanding22220000
Weighted Shares Outstanding22217265
Round Lot100
Updated date2024-05-05
Stats
Last 5 days
8-05
7-05
6-05
3-05
2-05
Last
3.48
3.645
3.7
3.671
3.584
Variance
-4.58%
-1.67%
-0.19%
4.14%
-2%
Open
3.647
3.707
3.707
3.525
3.657
Highest
3.65
3.765
3.785
3.754
3.719
Lowest
3.647
3.755
3.755
3.74
3.705
History
PeriodVarhighestlowest
1 week
-3.2%
3.719
3.585
1 month
-10.76%
4.179
3.269
3 month
-14.7%
4.26
3.269
6 month
2.61%
4.34
2.85
1 year
71.84%
2.08
0.17
3 year
-74.08%
14.22
0.17
5 year
-74.08%
14.22
0.17
10 year
-74.08%
14.22
0.17
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-10 2023-11-08 UNPUB
Assets 37,329,000 30,742,000 23,987,000 UNPUB
Current Assets 24,673,000 18,535,000 12,291,000 UNPUB
Current Liabilities 7,511,000 8,638,000 7,422,000 UNPUB
Equity 10,965,000 5,012,000 -1,190,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 10,965,000 5,012,000 -1,190,000 UNPUB
Liabilities 26,364,000 25,730,000 25,177,000 UNPUB
Liabilities And Equity 37,329,000 30,742,000 23,987,000 UNPUB
Noncurrent Assets 12,656,000 12,207,000 11,696,000 UNPUB
Noncurrent Liabilities 18,853,000 17,092,000 17,755,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-10 2023-11-08 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -8,305,000 -5,321,000 -6,466,000 UNPUB
Net Cash Flow, Continuing -8,305,000 -5,321,000 -6,466,000 UNPUB
Net Cash Flow From Financing Activities 44,000 1,188,000 21,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 44,000 1,188,000 21,000 UNPUB
Net Cash Flow From Investing Activities -46,000 -117,000 0 UNPUB
Net Cash Flow From Investing Activities, Continuing -46,000 -117,000 0 UNPUB
Net Cash Flow From Operating Activities -8,303,000 -6,392,000 -6,487,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -8,303,000 -6,392,000 -6,487,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-10 2023-11-08 UNPUB
Comprehensive Income/Loss -7,636,000 -7,581,000 -6,786,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -7,636,000 -7,581,000 -6,786,000 UNPUB
Other Comprehensive Income/Loss 0 0 0 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-10 2023-08-10 2023-11-08 UNPUB
Basic Earnings Per Share -1 -1 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,636,000 -7,581,000 -6,786,000 UNPUB
Income/Loss From Continuing Operations Before Tax -7,636,000 -7,581,000 -6,786,000 UNPUB
Income Tax Expense/Benefit 0 0 0 UNPUB
Interest Expense, Operating 344,000 355,000 373,000 UNPUB
Net Income/Loss -7,636,000 -7,581,000 -6,786,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -7,636,000 -7,581,000 -6,786,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -7,636,000 -7,581,000 -6,786,000 UNPUB
Operating Expenses UNPUB UNPUB UNPUB UNPUB
Operating Income/Loss -7,581,000 -7,470,000 -6,592,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues UNPUB UNPUB UNPUB UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-15 2022-11-08 2023-03-22
Assets 66,953,000 71,351,000 63,171,000 46,089,000
Current Assets 62,710,000 68,307,000 60,257,000 32,950,000
Current Liabilities 20,815,000 22,423,000 24,059,000 7,277,000
Equity 29,357,000 34,932,000 26,773,000 18,111,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 29,357,000 34,932,000 26,773,000 18,111,000
Liabilities 37,596,000 36,419,000 36,398,000 27,978,000
Liabilities And Equity 66,953,000 71,351,000 63,171,000 46,089,000
Noncurrent Assets 4,243,000 3,044,000 2,914,000 13,139,000
Noncurrent Liabilities 0 0 12,339,000 20,701,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-15 2022-11-08 2023-03-22
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -5,707,000 5,867,000 -8,830,000 -20,231,000
Net Cash Flow, Continuing -5,707,000 5,867,000 -8,830,000 -20,231,000
Net Cash Flow From Financing Activities 1,403,000 14,376,000 350,000 11,403,000
Net Cash Flow From Financing Activities, Continuing 1,403,000 14,376,000 350,000 11,403,000
Net Cash Flow From Investing Activities -3,000 -95,000 -108,000 -562,000
Net Cash Flow From Investing Activities, Continuing -3,000 -95,000 -108,000 -562,000
Net Cash Flow From Operating Activities -7,107,000 -8,414,000 -9,072,000 -31,072,000
Net Cash Flow From Operating Activities, Continuing -7,107,000 -8,414,000 -9,072,000 -31,072,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-15 2022-11-08 2023-03-22
Comprehensive Income/Loss -8,491,000 -9,168,000 -8,947,000 -35,709,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -8,491,000 -9,168,000 -8,947,000 -35,709,000
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-15 2022-11-08 2023-03-22
Basic Earnings Per Share -1 -1 -1 -3
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 -1 -3
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -8,491,000 -9,168,000 -8,947,000 -35,709,000
Income/Loss From Continuing Operations Before Tax -8,491,000 -9,168,000 -8,947,000 -35,709,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating 333,000 464,000 389,000 1,618,000
Net Income/Loss -8,491,000 -9,168,000 -8,947,000 -35,709,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -8,491,000 -9,168,000 -8,947,000 -35,709,000
Net Income/Loss Available To Common Stockholders, Basic -8,491,000 -9,168,000 -8,947,000 -35,709,000
Operating Expenses UNPUB UNPUB UNPUB UNPUB
Operating Income/Loss -8,161,000 -8,774,000 -8,771,000 -34,640,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues UNPUB UNPUB UNPUB UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-29
Assets UNPUB 75,497,000 67,142,000 73,238,000
Current Assets UNPUB 70,494,000 62,557,000 68,963,000
Current Liabilities UNPUB 9,794,000 6,203,000 20,026,000
Equity UNPUB 48,114,000 43,536,000 36,117,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 48,114,000 43,536,000 36,117,000
Liabilities UNPUB 27,383,000 23,606,000 37,121,000
Liabilities And Equity UNPUB 75,497,000 67,142,000 73,238,000
Noncurrent Assets UNPUB 5,003,000 4,585,000 4,275,000
Noncurrent Liabilities UNPUB 0 17,403,000 17,095,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-29
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB 61,449,000 -8,697,000 33,009,000
Net Cash Flow, Continuing UNPUB 61,443,000 -8,608,000 33,009,000
Net Cash Flow From Financing Activities UNPUB 55,883,000 3,167,000 59,063,000
Net Cash Flow From Financing Activities, Continuing UNPUB 55,883,000 3,167,000 59,063,000
Net Cash Flow From Investing Activities UNPUB -92,000 14,000 -97,000
Net Cash Flow From Investing Activities, Continuing UNPUB -92,000 14,000 -97,000
Net Cash Flow From Operating Activities UNPUB 5,652,000 -11,789,000 -25,957,000
Net Cash Flow From Operating Activities, Continuing UNPUB 5,652,000 -11,789,000 -25,957,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-29
Comprehensive Income/Loss UNPUB -7,058,000 -8,199,000 -28,302,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -7,058,000 -8,199,000 -28,302,000
Other Comprehensive Income/Loss UNPUB 0 -89,000 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-12 2021-11-10 2022-03-29
Basic Earnings Per Share UNPUB UNPUB UNPUB -7
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB -7
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -7,058,000 -8,110,000 -28,302,000
Income/Loss From Continuing Operations Before Tax UNPUB -7,058,000 -8,110,000 -28,302,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB 276,000 437,000 1,282,000
Net Income/Loss UNPUB -7,058,000 -8,110,000 -28,302,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -7,058,000 -8,110,000 -28,302,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -7,058,000 -8,110,000 -28,302,000
Operating Expenses UNPUB UNPUB UNPUB UNPUB
Operating Income/Loss UNPUB -6,785,000 7,736,000 -26,986,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB UNPUB UNPUB UNPUB
Calendar
9 May 2024 (Time UTC) Actual Previous Consensus
★
12:00
United States
★
11:30
United States
5.275
5.270
★
11:30
United States
5.270
5.275
★
11:30
United States
★
11:30
United States
★
10:30
United States
MAY 03
79000000000.000
59000000000.000
87000000000.000
★
10:30
United States
MAY 03
★★
10:00
United States
★
08:30
United States
MAY 03
215000.000
210250.000
★★
08:30
United States
MAY 03
231000.000
209000.000
212000.000
★
08:30
United States
APR 26
1785000.000
1768000.000
1790000.000
★
07:30
United States
MAY 03
★★
07:30
United States
MAY 03
★
07:30
United States
APR 26
8 May 2024 (Time UTC) Actual Previous Consensus
★
13:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:TPST240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:TPST240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:TPST240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:TPST240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:TPST240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:TPST240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:TPST240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:TPST240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:TPST240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:TPST240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:TPST240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:TPST240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:TPST240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:TPST240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:TPST240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:TPST240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:TPST240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:TPST240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:TPST240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:TPST240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:TPST240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:TPST240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:TPST240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:TPST240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:TPST231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:TPST231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:TPST231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:TPST231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:TPST231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:TPST231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
News Stream
Stocks Changes in company's own shares
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 5,400 shares of its common stock under the Company’s 2023 Inducement Plan.
GlobeNewswire Inc. • 1w ago
News Clinical Study
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
BRISBANE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Cancer Research Communications published positive clinical data from the dose-escalation Phase 1 trial of TPST-1120 in an article titled “First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.” The data showed that TPST-1120 demonstrated clinical activity, including tumor shrinkage, even in PD-1 inhibitor refractory and immune compromised cancers, and was well tolerated both as monotherapy and in combination with nivolumab. These earlier Phase 1 data complement the positive Phase 1b/2 data reported in October 2023 from a global randomized study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, which showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations.
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Tempest Reports Year End 2023 Financial Results and Provides Business Update
BRISBANE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the year ended 2023 and provided a corporate update.
GlobeNewswire Inc. • 1mo ago
News Clinical Study
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma (RCC) at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, CA.
GlobeNewswire Inc. • 2mo ago
Stocks Stock Market News
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that the Compensation Committee of the Company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 45,500 shares of its common stock under the Company’s 2023 Inducement Plan.
GlobeNewswire Inc. • 3mo ago
Stocks Changes in company's own shares
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that on January 3, 2024 the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase 4,500 shares of its common stock under the Company’s 2023 Inducement Plan. The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
GlobeNewswire Inc. • 4mo ago
Stocks Changes in company's own shares
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase 7,650 shares of its common stock under the Company’s 2023 Inducement Plan.
GlobeNewswire Inc. • 5mo ago
Calendar Calendar of Events
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023 at 3:00 p.m. ET.
GlobeNewswire Inc. • 5mo ago
Stocks Earnings Releases and Operating Results
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
BRISBANE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
GlobeNewswire Inc. • 6mo ago
News News
Ericsson shares drop on profit warning as NetScout stock slides on outlook cut
Ericsson, Nokia, ServisFirst Bancshares and NetScout Systems shares were active.
MarketWatch • 6mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT